IGM is the latest biotech to focus on the potential for T cell engagers to treat inflammatory conditions. Elsewhere, Metsera signed a manufacturing deal and UCB started a first-of-its-kind trial.

Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the ...

A judge has rejected a request to throw out the conviction of a movie armorer in the fatal shooting of a cinematographer by ...

Some officials are calling for renewed restrictions on syringe service programs in Maine, saying they have contributed to the rise in used needles littering city streets. But harm reduction experts ...

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / (NASDAQ:MRNA) today announced that the first participant in the U.S. has ...

Moderna also anticipates reporting interim Phase III CMVictory data on its mRNA-1647 candidate within the year and is preparing to commence a Phase III trial for its norovirus vaccine mRNA-1403.

Key programs going forward will be from the latent vaccines portfolio, such as the Phase III assets mRNA-1403 for norovirus and mRNA-1647 for cytomegalovirus. The goal has been for Moderna to start ...

With finanzwire.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock ...

[10] A Phase 1 trial designed to evaluate the safety, reactogenicity and immunogenicity of a trivalent norovirus vaccinecandidate, mRNA-1403, in participants 18 to 49 years of age and 60 to 80 ...